The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

Childhood cancer survival: A report from the United Kingdom Childhood Cancer Study

(2010) W. Thomas Johnston et al.   Cancer Epidemiology

Biology and Treatment of Acute Lymphoblastic Leukemia

(2010) Rob Pieters et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

(2010) Anjali Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma

(2009) Akihiro Takeshita et al.   BRITISH JOURNAL OF HAEMATOLOGY

Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study

(2009) Christian M. Zwaan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation

(2009) Ching-Hon Pui et al.   NEW ENGLAND JOURNAL OF MEDICINE

Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia

(2008) B F Goemans et al.   LEUKEMIA